Japer Therapeutics, Inc. Warrants(JSPRW)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
- Exchange
- XNAS
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma…
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -14.72% | 5 |
| Feb | +17.16% | 5 |
| Mar | +6.67% | 5 |
| Apr | -20.83% | 5 |
| May | +0.79% | 5 |
| Jun | +9.00% | 5 |
| Jul | -13.20% | 4 |
| Aug | +1.15% | 4 |
| Sep | -10.63% | 5 |
| Oct | +2.60% | 5 |
| Nov | -0.30% | 5 |
| Dec | -30.69% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.80
- Correlation (SPY)
- 4.2%
- R²
- 0.00
- Ann. Volatility
- 236.4%
- SPY Volatility
- 12.4%
Moderate volatility - stock generally follows market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-02-10 | Jeetinder Singh Mahal | CEO and President | Grant (A) | +500,000 opt | — | EDGAR | |
| 2026-01-05 | HERB CROSS | Chief Financial Officer | Grant (A) | +90,000 opt | — | EDGAR | |
| 2026-01-05 | RON MARTELL | President, CEO and Director | Grant (A) | +234,000 opt | — | EDGAR | |
| 2026-01-05 | Jeetinder Singh Mahal | Chief Operating Officer | Grant (A) | +90,000 opt | — | EDGAR | |
| 2025-09-24 | RON MARTELL | President and CEO | Buy (P) | +41,000 | $2.43 | $99.6K | EDGAR |
| 2025-09-24 | Judith Anne Shizuru | Director | Buy (P) | +41,000 | $2.43 | $99.6K | EDGAR |
| 2025-09-24 | Svetlana Lucas | Director | Buy (P) | +20,000 | $2.43 | $48.6K | EDGAR |
| 2025-09-24 | THOMAS G WIGGANS | Director | Buy (P) | +41,000 | $2.43 | $99.6K | EDGAR |
| 2025-07-03 | Chris Nolet | Director | Grant (A) | +7,500 opt | — | EDGAR | |
| 2025-07-03 | Judith Anne Shizuru | Director | Grant (A) | +7,500 opt | — | EDGAR | |
| 2025-07-03 | KURT VON EMSTER | Director | Grant (A) | +7,500 opt | — | EDGAR | |
| 2025-07-03 | THOMAS G WIGGANS | Director | Grant (A) | +7,500 opt | — | EDGAR | |
| 2025-07-03 | Svetlana Lucas | Director | Grant (A) | +7,500 opt | — | EDGAR | |
| 2025-07-03 | Scott C. Brun | Director | Grant (A) | +7,500 opt | — | EDGAR | |
| 2025-07-03 | Vishal Kapoor | Director | Grant (A) | +7,500 opt | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Carlyle Investment Management LLC | 10%+ Owner | 8,761,891 | $117.4K | $42.30M | 1 | 2023-01-31 |
| 2 | Qiming U.S. Healthcare Fund II, L.P. | 10%+ Owner | 8,519,648 | $114.2K | $16.00M | 1 | 2023-04-11 |
| 3 | ROCHE HOLDING LTD | 10%+ Owner | 4,549,606 | $61.0K | -$283.5K | 1 | 2023-01-26 |
| 4 | BALAJI VENKATARAMAN | 2,300,000 | $30.8K | $0 | 1 | 2021-09-28 | |
| 5 | HOWARD I HOFFEN | 2,300,000 | $30.8K | $0 | 1 | 2021-09-28 | |
| 6 | Amplitude Healthcare Holdings LLC | 10%+ Owner | 2,300,000 | $30.8K | $0 | 1 | 2021-09-28 |
| 7 | Kenneth F Clifford | 2,300,000 | $30.8K | $0 | 1 | 2021-09-28 | |
| 8 | Velan Capital Master Fund LP | 1,188,500 | $15.9K | $40.79M | 1 | 2024-02-09 | |
| 9 | LLP Abingworth | 10%+ Owner | 1,066,189 | $14.3K | $24.61M | 2 | 2024-02-12 |
| 10 | Judith Anne Shizuru | Director | 156,901 | $2.1K | $99.6K | 6 | 2025-09-24 |
| 11 | RON MARTELL | President, CEO and Director | 74,118 | $993 | $99.6K | 12 | 2026-01-05 |
| 12 | William Lis | Director | 53,521 | $717 | -$120.5K | 6 | 2023-10-13 |
| 13 | THOMAS G WIGGANS | Director | 46,000 | $616 | $130.7K | 7 | 2025-09-24 |
| 14 | Chris Nolet | Director | 32,500 | $436 | $0 | 5 | 2025-07-03 |
| 15 | Jeetinder Singh Mahal | CEO and President | 25,009 | $335 | -$99.4K | 16 | 2026-02-10 |
| 16 | Lawrence Otto Klein | Director | 24,500 | $328 | $0 | 3 | 2023-06-08 |
| 17 | Anna Louise French | Director | 23,750 | $318 | -$10.4K | 5 | 2024-06-10 |
| 18 | KURT VON EMSTER | Director | 21,175 | $284 | -$13.5K | 6 | 2025-07-03 |
| 19 | Svetlana Lucas | Director | 20,000 | $268 | $48.6K | 3 | 2025-09-24 |
| 20 | Edwin Jonathan Tucker | Chief Medical Officer | 400 | $5 | $0 | 5 | 2025-06-06 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.